Cacicedo Jon, Casquero Francisco, Martinez-Indart Lorea, Del Hoyo Olga, Iturriaga Alfonso Gómez de, Muruzabal Irma, Carvajal Claudia, Bóveda Elsira, Ruiz Blanca, Loayza Armando, Usategui Begoña, Lasso Aurora, Hortelano Eduardo, Bilbao Pedro
Department of Radiation Oncology, Cruces University Hospital, Baracaldo, Vizcaya, Spain.
Department of Statistics and Epidemiology, Cruces University Hospital, Baracaldo, Vizcaya, Spain.
Rep Pract Oncol Radiother. 2012 Aug 24;17(5):269-75. doi: 10.1016/j.rpor.2012.07.017. eCollection 2012 Sep.
To identify risk factors that influence weight loss in patients receiving radiotherapy.
It is a well-known fact that cancer patients can be affected by malnutrition at the onset of the disease and during treatment due to the toxicity. Pretreatment weight loss alone does not predict those who will need nutritional supplementation. Instead, a variety of nutritional and tumor related factors needs to be taken into account.
A retrospective study was conducted on 129 patients with different tumor locations. Weight loss was evaluated during radiotherapy and one month after treatment. The impact of age, ECOG, chemotherapy, pretreatment weight loss, tumor location, previous surgery and TNM were analyzed. We aimed to identify a high-risk group of patients before starting treatment.
The average net weight loss during radiotherapy and one month after treatment for this group of patients was 0.68 kg and 1.6 kg, respectively. Median weight loss during radiotherapy was 2.6 kg for head and neck (HN) patients and 0.27 kg for other tumor sites (p = 0.028). Median weight loss one month after radiotherapy was 3.7 kg for HN patients and 1.1 kg for the rest of the patients (p = 0.034). The median weight loss one month after treatment was 3.2 kg for patients receiving chemotherapy and 0.5 kg for those patients who did not receive chemotherapy (p < 0.001). A regression analysis determined that HN tumor location and the use of chemotherapy were independent risk factors.
Nutritional status must be monitored and managed before, during and after treatment. A variety of nutritional and tumor-related factors must be considered. According to our results, head and neck tumors and the use of chemotherapy are the only two factors considered statistically significant. Because patients continue to lose weight after treatment, we recommend close surveillance after radiotherapy.
确定影响接受放疗患者体重减轻的风险因素。
众所周知,癌症患者在疾病初发时以及治疗期间可能会因毒性作用而受到营养不良的影响。仅治疗前体重减轻并不能预测哪些患者需要营养补充。相反,需要考虑多种营养和肿瘤相关因素。
对129例肿瘤部位不同的患者进行了一项回顾性研究。在放疗期间和治疗后1个月评估体重减轻情况。分析了年龄、美国东部肿瘤协作组(ECOG)状态、化疗、治疗前体重减轻、肿瘤部位、既往手术和TNM分期的影响。我们旨在在开始治疗前确定高危患者群体。
该组患者放疗期间和治疗后1个月的平均净体重减轻分别为0.68千克和1.6千克。头颈部(HN)患者放疗期间的中位体重减轻为2.6千克,其他肿瘤部位为0.27千克(p = 0.028)。放疗后1个月,HN患者的中位体重减轻为3.7千克,其余患者为1.1千克(p = 0.034)。接受化疗的患者治疗后1个月的中位体重减轻为3.2千克,未接受化疗的患者为0.5千克(p < 0.001)。回归分析确定HN肿瘤部位和化疗的使用是独立的风险因素。
治疗前、治疗期间和治疗后必须监测和管理营养状况。必须考虑多种营养和肿瘤相关因素。根据我们的结果,头颈部肿瘤和化疗的使用是仅有的两个具有统计学意义的因素。由于患者在治疗后仍会继续体重减轻,我们建议放疗后密切监测。